1. Home
  2. FEBO vs BGLC Comparison

FEBO vs BGLC Comparison

Compare FEBO & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fenbo Holdings Limited

FEBO

Fenbo Holdings Limited

N/A

Current Price

$1.17

Market Cap

11.8M

Sector

N/A

ML Signal

N/A

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$2.44

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEBO
BGLC
Founded
1993
2017
Country
Hong Kong
Malaysia
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
10.1M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
FEBO
BGLC
Price
$1.17
$2.44
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.9K
8.1K
Earning Date
04-24-2026
04-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.78
EPS
N/A
N/A
Revenue
N/A
$9,510,646.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.23
52 Week High
$1.48
$15.19

Technical Indicators

Market Signals
Indicator
FEBO
BGLC
Relative Strength Index (RSI) 55.39 47.96
Support Level $1.04 $2.12
Resistance Level $1.19 $2.73
Average True Range (ATR) 0.05 0.15
MACD 0.01 0.04
Stochastic Oscillator 68.45 52.51

Price Performance

Historical Comparison
FEBO
BGLC

About FEBO Fenbo Holdings Limited

Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: